16.1
Sistemas de administración de fármacos: Diferentes tipos
Los medicamentos orales convencionales, denominados formulaciones de liberación inmediata, o LI, están diseñados para liberar rápidamente su principio…
Las formulaciones convencionales de liberación inmediata liberan el principio activo inmediatamente al ingerirlo, lo que conduce a una absorción rápida. Sin embargo, las formulaciones que contienen fármacos poco solubles pueden mostrar una absorción más lenta.
Para superar estas limitaciones, se han diseñado formas de dosificación de liberación modificada para controlar los patrones de liberación de fármacos. Existen varios tipos de productos de medicamentos orales de liberación modificada.
Las formulaciones de liberación prolongada están diseñadas para mantener la liberación del fármaco, mantener los niveles terapéuticos durante periodos más largos y reducir la frecuencia de la dosificación.
Las formulaciones de liberación retardada, a menudo con recubrimientos entéricos, protegen el fármaco del ambiente ácido del estómago y aseguran la liberación del fármaco solo en los intestinos, optimizando los perfiles de absorción.
Las formulaciones de liberación dirigida administran fármacos a sitios específicos del cuerpo, maximizando los efectos terapéuticos y minimizando la exposición sistémica. Estas formulaciones pueden diseñarse para una liberación inmediata o sostenida del fármaco.
Las pastillas que se desintegran oralmente se disuelven rápidamente en la saliva, permitiendo la absorción directa de fármacos bucales y efectos terapéuticos más rápidos. Son ideales para pacientes que tienen dificultades para tragar pastillas convencionales.
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between immediate-release and modified-release drug formulations?
Immediate-release formulations release the active pharmaceutical ingredient promptly upon ingestion, leading to rapid absorption and quick therapeutic effects. Modified-release formulations deliberately alter drug release rate and timing to achieve specific therapeutic goals, maintain consistent drug levels, and improve patient adherence by reducing dosing frequency.
Q2: How do extended-release formulations maintain therapeutic drug levels?
Extended-release formulations utilize advanced technologies such as matrix systems and osmotic pumps to control drug release gradually over extended periods. Matrix systems embed the drug in a dissolving matrix, while osmotic pumps release drug through a semipermeable membrane opening, maintaining steady bloodstream levels and minimizing fluctuations.
Q3: Why are enteric coatings used in delayed-release formulations?
Enteric coatings protect drugs from the acidic stomach environment by resisting stomach acid and ensuring release only in the intestines. This approach optimizes absorption profiles and reduces gastric irritation, exemplified by enteric-coated aspirin, which enhances therapeutic efficacy while mitigating side effects.
Q4: What are the advantages of targeted-release drug delivery systems?
Targeted-release formulations deliver drugs directly to specific physiological sites using advanced carriers like liposomes or nanoparticles, enhancing therapeutic effects while minimizing systemic exposure. This precise delivery and localized action is particularly beneficial in treatments like cancer therapy, reducing unwanted side effects.
Q5: How do orally disintegrating tablets benefit patients with swallowing difficulties?
Orally disintegrating tablets dissolve rapidly in saliva, facilitating quick drug absorption without requiring water. This formulation enables direct buccal drug absorption and quicker therapeutic effects, making them particularly suitable for patients with swallowing difficulties or those unable to take conventional tablets.
Q6: What factors affect drug absorption in immediate-release formulations?
Drug absorption in immediate-release formulations depends on the drug's physicochemical properties. Poorly soluble drugs may exhibit slower absorption due to gradual dissolution in the gastrointestinal tract, while prodrugs require metabolic conversion to activate their effects, introducing delays in onset times.
Q7: How do modified-release formulations improve patient adherence?
Modified-release formulations reduce dosing frequency by maintaining therapeutic drug levels over extended periods, allowing patients to take medication less often. This consistent drug delivery minimizes fluctuations in blood concentration, improving treatment outcomes and making medication regimens easier for patients to follow.